ArticleFrontiers in oncology2025
Diffuse large B-cell lymphoma combined with two solid tumors: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of multiple primary tumors in a 67-year-old male. The patient was treated surgically for a lumbar disc herniation with intraoperative findings of L5 nerve root tumor, and postoperative pathology confirmed a diagnosis of diffuse large B-cell lymphoma (DLBCL). Three months later, the patient was further pathologically diagnosed with prostate cancer. The multidisciplinary treatment team devised a staged therapeutic strategy: firstly, 2 cycles of R-CHOP chemotherapy for DLBCL, followed by local radiotherapy for the residual lesion of lumbar spine tumor, and then 2 cycles of R-MTX-CHOP chemotherapy in sequence; after the DLBCL was controlled, the patient underwent radical prostatectomy, which was followed by adjuvant endocrine therapy and pelvic lymph node radiotherapy. Post-treatment evaluation showed complete remission (CR) in both tumors. After five years of disease-free survival, the patient presented with enlarged cervical lymph nodes in October 2022. A biopsy confirmed DLBCL recurrence. The treatment team administered six cycles of R-GemOx chemotherapy, followed by maintenance therapy with the targeted agent Orelabrutinib. Subsequent assessments confirmed a second CR. In September 2024, a colonoscopy revealed a rectal tumor, which was pathologically diagnosed as rectal cancer. The patient underwent radical surgery, and the pathological staging was determined to be stage I. According to the literature search, this is the first reported case of triple primary malignancies involving DLBCL, prostate cancer and rectal cancer, which provides valuable experience in the clinical diagnosis and treatment of such rare cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.